CAMBRIDGE, UK – 1 March 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, and Dr Xavier Jacq, VP Scientific Affairs, are scheduled to present at the following events:
(1) 6th Ubiquitin Research and Drug Discovery GTC Conference, 29 February-1 March, 2016, San Diego, CA
Dr Xavier Jacq, VP Scientific Affairs, to present on Tuesday, 1st March 2016 at 11.25 am PST on “Discovery of highly selective DUB inhibitors with in vivo pre-clinical activity”
This conference provides a forum for researchers from both industry and academia to learn about recent advances in basic science and drugs that target the ubiquitin/proteasome system. Topics will include autophagy in cancer, developments with deubiquitinating enzymes, and novel drug targets in the ubiquitin system.
(2) Cowen and Company 36th Annual Health Care Conference, 7-9 March 2016, The Boston Marriott Copley Place, Boston, Massachusetts
Anker Lundemose, CEO, to present on Tuesday, 8th March 2016 at 3.30 pm EST
Cowen and Company’s conferences belong to major industry events and connects top institutional investors with leading companies in the healthcare sector.
(3) 9th Annual European Life Science CEO Forum & Exhibition, 15-16 March 2016, Hilton Zurich Airport Hotel, Switzerland
Anker Lundemose, CEO, to speak on Tuesday, 15th March 2016 at 2.00 pm CET on the panel “Platform Technologies & Novel Therapeutics Panel” as well as present an overview of MISSION therapeutics at 4.45 pm CET
The event brings together venture-funded and small-cap companies as well as leading investors, pharmas, and scientific thought leaders. The event includes sessions on Public Markets and M&A, Investment, Partnering as well as panels on: Clinical Development, Regulation in Europe, Innovation and BD&L in Oncology as well as Platform Technologies & Novel Therapeutics.
(4) Keystone Symposia on Molecular and Cellular Biology: Ubiquitin Signaling (X3), 13-17 March 2016, Whistler Conference Centre, Whistler, British Columbia, Canada
Dr Xavier Jacq, VP Scientific Affairs, to present on Monday, 14th March 2016 at 5.00 pm PST on “Role of Ubiquitylation in Control of Autophagy, Short Talk: Inhibitors of USP30 as a Potential Treatment of Parkinson’s disease And Other Mitochondrial Dysfunctions”
Organized by Keystone Symposia on Molecular and Cellular Biology, the conference aims to connect the scientific community and accelerate life science discovery. The meeting will focus on how ubiquitylation controls processes such as autophagy, neurodegenerative diseases, hypertension and the immune system.
For more information:
MISSION Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497199
Mary Clark, Eva Haas, Hollie Vile
Tel: +44 (0) 20 7862 6390
NOTES TO EDITORS:
About MISSION Therapeutics
MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and non-malignant disease. It has built a world-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
DUBs are involved in multiple cellular processes, including DNA damage response and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs for treating cancer and other unmet medical needs, including neurodegenerative disease, muscle wasting and infectious disease. Despite significant efforts within the pharmaceutical sector, there is a lack of DUB inhibitors in clinical development.
MISSION’s leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge. Professor Steve Jackson at Cancer Research UK laboratories and the Gurdon Institute, University of Cambridge is the scientific founder of MISSION and is the Chief Scientific Officer of the Company.
MISSION Therapeutics has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. MISSION is based at the Babraham Research Campus, south of Cambridge.